Vasopressor Effects in Anesthetized Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02713087 |
Recruitment Status :
Completed
First Posted : March 18, 2016
Last Update Posted : October 26, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Project title: Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients with Cerebral Tumors
Sponsor-investigator: Klaus Ulrik Koch M.D.
Sponsor: Department of Anesthesia Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
Objective:
To investigate whether phenylephrine and ephedrine causes different alterations in microcirculation and oxygenation, as measured with MRI and PET, in anesthetized patients with brain tumors. Using MRI and PET, the study will assess whether there is a difference in deoxyhemoglobin concentration (Bold signal), CTTH, cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) between ephedrine and phenylephrine
Method:
Double blinded controlled randomized clinical trial. Either phenylephrine or ephedrine are infused intravenously under general anesthesia. MRI is performed in 20 patients before and after infusion. PET/CT is performed in 20 patients before and after infusion. BIS and NIRS monitoring will be used in either scanner. After scanning patients are transported to the operating theatre and the craniotomy is performed. After removal of the bone flap subdural ICP is measured and recorded.
MRI to analyze CBF, CTH, max.CMRO2, maxOEF, CBV and grey-scale ADC before and after ephedrine and phenylephrine. PET/CT to analyze CBF and CMRO2 before and after ephedrine and phenylephrine and calculation of OEF. During each PET/CT scan session oxygen saturation and hemoglobin concentration is measured.
Data from the proposed studies will add substantial new knowledge to the investigators current understanding of the effects of vasopressors on cerebral circulation. This information will aid the neuroanesthesiologist, neurointensivist and the neurosurgeon in the choice of the optimal method to manage cerebral perfusion pressure during craniotomy for brain tumor.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Tumor | Drug: Ephedrine Drug: Phenylephrine | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors |
Study Start Date : | September 2015 |
Actual Primary Completion Date : | November 2017 |
Actual Study Completion Date : | November 2017 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Ephedrine |
Drug: Ephedrine
Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20% |
Active Comparator: Phenylephrine |
Drug: Phenylephrine
Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20% |
- Capillary Transit Time Heterogeneity [ Time Frame: 4 Years ]
- Cerebral Metabolic Rate of Oxygen [ Time Frame: 4 Years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled for supine-positioned elective craniotomy for supratentorial malignant and non-malignant brain tumors 3 cm or larger (measured as the largest diameter in any plane on MR images)
- ASA (American Society of Anesthesiologist) status 1-3 (27)
- Written informed consent from participating patients
Exclusion Criteria:
- Age younger than 18 yrs. or older than 75 yrs.
- Pregnancy or nursing (negative pregnancy blood test)
- History of allergic reactions to phenylephrine or ephedrine
- eGFR < 60ml/min/1.73m2

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02713087
Denmark | |
Aarhus University Hospital | |
Aarhus, Jylland, Denmark, 8000 |
Study Director: | Leif Oestergaard, Professor | University of Aarhus |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT02713087 |
Other Study ID Numbers: |
Vasobrain01 |
First Posted: | March 18, 2016 Key Record Dates |
Last Update Posted: | October 26, 2018 |
Last Verified: | October 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases Phenylephrine Oxymetazoline Ephedrine Cardiotonic Agents Mydriatics Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Sympathomimetics Vasoconstrictor Agents Nasal Decongestants Respiratory System Agents Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Central Nervous System Stimulants |